A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
26
5
2020
medline:
22
9
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Metformin is a widely prescribed antidiabetic BCS Class III drug (low permeability) that depends on active transport for its absorption and disposition. It is recommended by the US Food and Drug Administration as a clinical substrate of organic cation transporter 2/multidrug and toxin extrusion protein for drug-drug interaction studies. Cimetidine is a potent organic cation transporter 2/multidrug and toxin extrusion protein inhibitor. The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure. Physiologically based pharmacokinetic models were developed in PK-Sim The established physiologically based pharmacokinetic models adequately describe the available clinical data, including the investigated drug-gene interaction, drug-drug interaction, and drug-drug-gene interaction studies, as well as the metformin exposure during renal impairment. All modeled drug-drug interaction area under the curve and maximum concentration ratios are within 1.5-fold of the observed ratios. The clinical data of renally impaired patients shows the expected increase in metformin exposure with declining kidney function, but also indicates counter-regulatory mechanisms in severe renal disease; these mechanisms were implemented into the model based on findings in preclinical species. Whole-body physiologically based pharmacokinetic models of metformin and cimetidine were built and qualified for the prediction of metformin pharmacokinetics during drug-gene interaction, drug-drug interaction, and different stages of renal disease. The model files will be freely available in the Open Systems Pharmacology model repository. Current guidelines for metformin treatment of renally impaired patients should be reviewed to avoid overdosing in CKD3 and to allow metformin therapy of CKD4 patients.
Sections du résumé
BACKGROUND
Metformin is a widely prescribed antidiabetic BCS Class III drug (low permeability) that depends on active transport for its absorption and disposition. It is recommended by the US Food and Drug Administration as a clinical substrate of organic cation transporter 2/multidrug and toxin extrusion protein for drug-drug interaction studies. Cimetidine is a potent organic cation transporter 2/multidrug and toxin extrusion protein inhibitor.
OBJECTIVE
The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure.
METHODS
Physiologically based pharmacokinetic models were developed in PK-Sim
RESULTS
The established physiologically based pharmacokinetic models adequately describe the available clinical data, including the investigated drug-gene interaction, drug-drug interaction, and drug-drug-gene interaction studies, as well as the metformin exposure during renal impairment. All modeled drug-drug interaction area under the curve and maximum concentration ratios are within 1.5-fold of the observed ratios. The clinical data of renally impaired patients shows the expected increase in metformin exposure with declining kidney function, but also indicates counter-regulatory mechanisms in severe renal disease; these mechanisms were implemented into the model based on findings in preclinical species.
CONCLUSIONS
Whole-body physiologically based pharmacokinetic models of metformin and cimetidine were built and qualified for the prediction of metformin pharmacokinetics during drug-gene interaction, drug-drug interaction, and different stages of renal disease. The model files will be freely available in the Open Systems Pharmacology model repository. Current guidelines for metformin treatment of renally impaired patients should be reviewed to avoid overdosing in CKD3 and to allow metformin therapy of CKD4 patients.
Identifiants
pubmed: 32449077
doi: 10.1007/s40262-020-00896-w
pii: 10.1007/s40262-020-00896-w
pmc: PMC7658088
doi:
Substances chimiques
Hypoglycemic Agents
0
Cimetidine
80061L1WGD
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1419-1431Références
AAPS J. 2013 Oct;15(4):1012-24
pubmed: 23835676
Diabetes Obes Metab. 2012 Oct;14(10):963-5
pubmed: 22564555
Am J Med. 1969 Jan;46(1):1-11
pubmed: 4952757
Eur J Pharm Sci. 2016 Jun 10;88:70-82
pubmed: 27019345
Clin Pharmacol Ther. 2008 Nov;84(5):559-62
pubmed: 18401339
Br J Clin Pharmacol. 1981 Aug;12(2):235-46
pubmed: 7306436
Mol Pharm. 2015 Dec 7;12(12):4301-10
pubmed: 26528626
J Clin Pharmacol. 2012 Jan;52(1 Suppl):91S-108S
pubmed: 22232759
Pharmacogenet Genomics. 2011 Dec;21(12):837-50
pubmed: 21989078
Clin Pharmacokinet. 2013 May;52(5):373-84
pubmed: 23475568
Clin Pharmacol Ther. 1981 Jun;29(6):737-43
pubmed: 7226705
Biopharm Drug Dispos. 2019 Jan;40(1):3-11
pubmed: 30488476
J Clin Pharmacol. 1995 Nov;35(11):1094-102
pubmed: 8626883
Drug Metab Dispos. 2007 Oct;35(10):1956-62
pubmed: 17600084
Clin Pharmacokinet. 1983 Nov-Dec;8(6):463-95
pubmed: 6418428
J Nucl Med. 2016 Dec;57(12):1920-1926
pubmed: 27469359
Clin Pharmacokinet. 2015 Feb;54(2):179-93
pubmed: 25316573
Drug Metab Dispos. 2016 Dec;44(12):1920-1924
pubmed: 27621205
CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2:e65
pubmed: 23945606
Clin Pharmacokinet. 2011 Feb;50(2):81-98
pubmed: 21241070
Clin Pharmacol Ther. 2013 Feb;93(2):186-94
pubmed: 23267855
Pharmacogenet Genomics. 2008 Jul;18(7):637-45
pubmed: 18551044
Diabetes Res Clin Pract. 1988 Feb 19;4(3):223-9
pubmed: 3359923
Drug Metab Dispos. 2009 Jun;37(6):1312-8
pubmed: 19251820
Br J Clin Pharmacol. 2018 Sep;84(9):1941-1949
pubmed: 29665130
Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1027-35
pubmed: 23960029
J Pharmacol Exp Ther. 2012 Feb;340(2):393-403
pubmed: 22072731
Diabetes Care. 2018 Mar;41(3):547-553
pubmed: 29305402
Br J Clin Pharmacol. 1987 May;23(5):545-51
pubmed: 3593625
Acta Pharmacol Sin. 2012 Nov;33(11):1359-71
pubmed: 23085739
Pharmacogenet Genomics. 2013 Oct;23(10):526-34
pubmed: 23873119
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):396-406
pubmed: 30821133
Clin Pharmacol Ther. 1978 Dec;24(6):683-93
pubmed: 710026
Pharmacogenet Genomics. 2009 Jul;19(7):497-504
pubmed: 19483665
J Clin Pharmacol. 1996 Nov;36(11):1012-21
pubmed: 8973990
Am J Med. 1960 Jan;28:77-98
pubmed: 13804370
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):878-882
pubmed: 31671256
J Clin Pharmacol. 2000 Nov;40(11):1280-5
pubmed: 11075314
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):788-797
pubmed: 30270578
Eur J Clin Pharmacol. 1979 Sep;16(3):195-202
pubmed: 499320
J Pharm Sci. 2017 Sep;106(9):2245-2250
pubmed: 28495567
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8
pubmed: 16330770
Clin Pharmacol Ther. 2018 Mar;103(3):485-492
pubmed: 28738449
J Am Soc Nephrol. 2006 Aug;17(8):2127-35
pubmed: 16807400
Drug Metab Dispos. 2015 Mar;43(3):325-34
pubmed: 25504564
Clin Pharmacol Drug Dev. 2016 Jan;5(1):27-39
pubmed: 27119576
J Pharmacol Exp Ther. 2015 Mar;352(3):519-28
pubmed: 25563903